Skip to main content

Table 2 Correlation between CYP26A1 expression and the clinicopathological variables in head and neck squamous cell carcinoma patients via tissue microarray analysis

From: Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer

  

CYP26A1 expression

 

Variables

Cases (n)

Negative (%)

Positive (%)

P

Age (years)

    

  <60

59

31 (52.5)

28 (47.5)

0.136

  ≥60

61

41 (67.2)

20 (32.8)

 

Sex

    

  Male

104

61 (58.7)

43 (41.3)

0.586

  Female

16

11 (68.8)

5 (31.2)

 

Primary tumor status (pT)

    

  pT1

9

6 (66.7)

3 (33.3)

0.025*

  pT2

38

25 (65.8)

13 (34.2)

 

  pT3

35

25 (71.4)

10 (28.6)

 

  pT4

34

13 (38.2)

21 (61.8)

 

Lymph node involvement (pN)

    

  Absent

65

40 (61.5)

25 (38.5)

0.574

  Present

52

29 (55.8)

23 (44.2)

 

Distant metastasis (M)

    

  Absent

115

69 (60.0)

46 (40.0)

1.000

  Present

4

2 (50.0)

2 (50.0)

 

pTNM stage

    

  pStage I

7

5 (71.4)

2 (28.6)

0.015*

  pStage II

26

18 (69.2)

8 (30.8)

 

  pStage III

35

26 (74.3)

9 (25.7)

 

  pStage IV

49

21 (42.9)

28 (57.1)

 
  1. *Significantly different by the chi-square (χ2) test.
  2. Abbreviations: CYP26A1, cytochrome P450, family 26, subfamily A, polypeptide 1; pTNM, pathological tumor-node-metastasis.